NIDA CTN-0152: Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: a Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)
Latest Information Update: 23 Oct 2024
Price :
$35 *
At a glance
- Drugs Tirzepatide (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- 23 Oct 2024 New trial record